Julia M Berger,Martin Korpan,Carina Zierfuss et al.
Julia M Berger et al.
Extranodal diffuse large B-cell lymphoma: Clinical and molecular insights with survival outcomes from the multicenter EXPECT study [0.03%]
_EXPECT研究：关于结外弥漫性大B细胞淋巴瘤的临床、分子及生存预后多中心研究
Si-Yuan Chen,Peng-Peng Xu,Ru Feng et al.
Si-Yuan Chen et al.
Background: Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of aggressive non-Hodgkin's lymphoma with distinct clinical and molecular heterogeneity. DLBCL that arises in extranodal organs is particularly ...
Semaglutide impairs bioavailability of alectinib: a note of warning based on a cross-over pharmacokinetic drug-drug interaction study [0.03%]
司美格鲁肽影响阿莱替尼生物利用度：基于药代动力学药物相互作用交叉试验的警告
Niels Heersche,Daan A C Lanser,Esther Oomen-de Hoop et al.
Niels Heersche et al.
Neutrophils in cancer: At the crucial crossroads of anti-tumor and pro-tumor [0.03%]
中性粒细胞与肿瘤：反肿瘤和促肿瘤的十字路口
Wenpeng Cai,Tao Fan,Chu Xiao et al.
Wenpeng Cai et al.
Neutrophils are important components of the immune system and play a key role in defending against pathogenic infections and responding to inflammatory cues, including cancer. Their dysregulation indicates potential disease risk factors. Ho...
Risk of colorectal cancer and cancer-related mortality in type 2 diabetes patients treated with metformin, SGLT-2 inhibitors, or their combination [0.03%]
二甲双胍、SGLT2抑制剂或两者联合治疗2型糖尿病患者结直肠癌风险及癌症相关死亡率的前瞻性研究
Xianhua Mao,Ka-Shing Cheung,Jing-Tong Tan et al.
Xianhua Mao et al.
Novel molecular mechanisms of immune evasion in hepatocellular carcinoma: NSUN2-mediated increase of SOAT2 RNA methylation [0.03%]
肝细胞癌免疫逃逸的新分子机制：NSUN2介导的SOAT2 RNA甲基化增加
Jinhua Jiang,Feng Liu,Dan Cui et al.
Jinhua Jiang et al.
Background: Hepatocellular carcinoma (HCC) is a deadly malignancy known for its ability to evade immune surveillance. NOP2/Sun RNA methyltransferase family member 2 (NSUN2), an RNA methyltransferase involved in carcinogen...
Phase II study evaluating the safety and efficacy of neratinib and trastuzumab biosimilar in patients with HER2 mutated advanced solid tumors: KCSG AL20-17/KM23 trial [0.03%]
评估奈拉替尼和曲妥珠单抗生物类似物在HER2突变晚期实体瘤患者中的安全性和有效性的II期研究：KCSG AL20-17/KM23试验
Kyoungmin Lee,Kyung-Hun Lee,Dong-Wan Kim et al.
Kyoungmin Lee et al.
Enhancing antitumor immunity through the combination of cholesterolized TLR7 agonist liposomes and radiotherapy: a role for IL-1β and the inflammasome pathway [0.03%]
胆固醇化TLR7激动剂脂质体与放疗联合使用通过IL-1β和炎性小体途径增强抗肿瘤免疫作用
Xuejiao Han,Yuan Cheng,Dandan Wan et al.
Xuejiao Han et al.
Background: Radiotherapy (RT) is a key treatment modality in cancer therapy, utilizing high-energy radiation to directly kill tumor cells. Recent research has increasingly highlighted RT's potential to indirectly enhance ...
Xiangyi Kong,Xintong Xie,Juan Wu et al.
Xiangyi Kong et al.
Cancer immunotherapy offers renewed hope for treating this disease. However, cancer cells possess inherent mechanisms that enable them to circumvent each stage of the immune cycle, thereby evading anti-cancer immunity and leading to resista...
Deciphering the transcriptomic landscape of early HR+/HER2- breast cancer in very young women [0.03%]
揭秘非常年轻女性早期HR+/HER2-乳腺癌转录组景观
Iris Garrido-Cano,Marta Tapia,Juan Carbonell et al.
Iris Garrido-Cano et al.